Clinical Trial Details
| Trial ID: | L0473 |
| Source ID: | JPRN-jRCT1031180386 |
| Associated Drug: | Dapagliflozin |
| Title: | Comparison of Dapagliflozin and vitamin E Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, Open-Label Controlled Trial |
| Acronym: | -- |
| Status: | Recruiting |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Nonalcoholic fatty liver disease Nonalcoholic steatohepatit <br>NAFLD NASH type 2 DM |
| Interventions: | Medicine |
| Outcome Measures: | Change of serum AST, ALT, ALP, gammaGTP, type IV collagen, M2BPGi, Fib4 index, adverse effectChange of body weight, fasting plasma glucose (FPG), insulin, triacylglycerol (TG), non-esterified fatty acid, HDL-cholesterol, LDL-cholesterol, leptin, CAP, liver stiffness visceral fat amount |
| Sponsor/Collaborators: | Ikejima Kenichi |
| Gender: | All |
| Age: | >= 20age old<= 80age old |
| Phases: | Not applicable |
| Enrollment: | 40 |
| Study Type: | Interventional |
| Study Designs: | randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose |
| Start Date: | 20/03/2019 |
| Completion Date: | -- |
| Results First Posted: | -- |
| Last Update Posted: | 17 May 2021 |
| Locations: | Japan |
| URL: | https://jrct.niph.go.jp/latest-detail/jRCT1031180386 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D101 | Dapagliflozin | Chemical drug | DB06292 | SLC5A2 antagonist; SLC5A2 inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D388 | Vitamin E | Supplement | DB00163 | NR1I2; ALOX5; DGKA | Anti-inflammatory | Under clinical trials | Details |